Novartis is making a major investment in its U.S. operations. The company announced a $23 billion plan to expand manufacturing and research across the country over the next five years. The goal is to produce 100% of its key medicines for U.S. patients entirely within the United States — a significant jump from current levels.

What’s Related

The investment includes 10 facilities, 7 of them brand new, and is expected to create nearly 1,000 new jobs at Novartis and around 4,000 additional jobs across the U.S.

Here’s what Novartis plans to do between now and 2030:

• Establish a new $1.1 billion research hub in San Diego, CA, which will serve as the company’s West Coast innovation center. It’s expected to open between 2028 and 2029.
• Build four new manufacturing facilities in U.S. states (locations still to be announced), including three sites for biologics drug substances, drug products, device assembly, and packaging. The fourth site will focus on chemical drug substances, oral solid dosage forms, and packaging.
• Build two new radioligand therapy (RLT) manufacturing facilities in Florida and Texas.
• Expand three existing RLT facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA.

With this expansion, Novartis says it will have full U.S. manufacturing coverage across its key platforms, including small molecules, biologics, gene and cell therapies, and radioligand therapies. It also plans to bring its siRNA technology manufacturing to the U.S. for the first time.

“As a Swiss-based company with a significant presence in the U.S., these investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook,” said Vas Narasimhan, CEO of Novartis. “We are prepared for shifts in the external environment and fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.”

Novartis is the latest company to invest in U.S. manufacturing. Other companies include Johnson & Johnson ($55 billion), Hyundai ($21 billion), GE Aerospace ($1 billion), Schneider Electric ($700 million), and others.

The San Diego research site will complement the company’s existing hubs in Cambridge, Massachusetts, and Basel, Switzerland. It’s part of a larger plan to expand R&D and tap into top U.S. scientific talent. Novartis says its total U.S. investment, including this new initiative, will be close to $50 billion over the next five years.